Financing Growth at a Dental Support Organization

Opening a new location means leasehold improvements, dental equipment and working capital to cover the ramp period before a new practice reaches steady patient volume, all spent before that location generates meaningful revenue. This is a capital expenditure and ramp-financing need, typically better matched to a construction or equipment loan specific to the buildout, sized against the project itself, than to RBF, which advances against revenue you already have rather than revenue a new location hasn't generated yet.

Buying an existing practice to add to the group is a distinct transaction with its own financing tools, typically acquisition debt sized against the target practice's cash flow and a valuation multiple, sometimes paired with seller financing. Neither venture debt nor RBF, as generally structured, is built for practice acquisition financing specifically, though a DSO that's raised institutional equity may use venture debt as part of a broader acquisition strategy's capital stack alongside dedicated acquisition debt.

Once a group of locations is established and generating steady, collectible revenue, RBF becomes a more realistic option for financing things like a shared services platform, marketing across the group, or working capital that scales with patient volume across existing practices, as opposed to funding a specific new location or acquisition. The advance gets sized against the group's collective trailing revenue, and lenders will typically want to see collections, not just billed revenue, given the reimbursement lag dental practices carry.

Dental insurance reimbursement can take weeks to settle depending on the payer and claim complexity, and a DSO with sloppy claims processing across multiple locations can end up carrying meaningfully more receivables than one with tight claims management, dollar for dollar the same patient volume. Before assuming the answer is a larger financing facility, audit claims denial rates and days-to-collect across your locations. Tightening claims processing often closes more of the cash gap than any lending product would, and it's a fix that compounds as you add locations rather than one you have to refinance for each new practice.

Venture debt fits a DSO that's raised institutional equity to fund its platform and management infrastructure, and wants runway for that corporate-level build, recruiting, technology, back-office systems, separate from the acquisition debt financing individual practice purchases. It's sized against the balance sheet the equity round created, giving the group flexibility that doesn't depend on any single location's collections.

Before financing anything, sort the request:

• Is this a de novo buildout, which needs project-specific construction or equipment financing?
• Is it an acquisition, which needs acquisition debt sized against the target's cash flow?
• Is it working capital or platform costs across an established group of collecting locations, where RBF becomes realistic?
• Have you audited claims processing and days-to-collect before assuming a bigger facility is the fix?

It's tempting to raise one large facility that covers de novo growth, the next acquisition and general working capital all at once, since it feels simpler than three separate conversations. In practice, lenders price each of these risks very differently, and blending them into one ask usually means paying acquisition-debt-level scrutiny and pricing on your working capital needs, or working-capital-level terms on a buildout that a construction lender would have financed more cheaply on its own. Founders who separate the asks, even when it means more paperwork upfront, generally end up with a lower blended cost of capital across the group than those who raise one large, generic facility to cover everything at once.

Recruiting and retaining dentists and specialists, particularly for a growing group competing with other DSOs and independent practices for the same talent pool, carries its own real cost: signing incentives, guaranteed compensation during ramp, and the marketing spend needed to keep a new provider's schedule filling up. This cost recurs with every hire and deserves the same explicit budgeting as de novo buildouts and acquisitions, rather than being absorbed silently into general working capital where it's harder to track against the return each new provider actually generates.